Dallas, TX, November 01, 2013 --(PR.com
)-- AveXis-BioLife is pleased to announce the launch of the company’s brand new website: www.avexisinc.com. The October 2013 unveiling of the website coincides with the company’s licensing of the gene therapy program from The Kaspar Laboratory for the treatment of Spinal Muscular Atrophy (SMA).
The new website offers a contemporary look and more user friendly experience. It features resources and functionality designed solely for the AveXis-BioLife extended community.
The website is an unlimited resource for those wanting information regarding Spinal Muscular Atrophy, treatment updates, clinical trials, gene delivery and investor relations. For those social media fanatics, you can follow them on Twitter and Facebook using the links on their homepage.
New additions to the website include: personal stories from families whose children have been diagnosed with SMA, specific information about their gene therapy treatments and the latest information hot off the press.
“SMA is a disease that affects children. To see Sophia Gaynor and Avery Pitzen on the website makes me work even harder each day!” said Chief Executive Office John Carbona.
To see the new website, please visit: www.avexisinc.com
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
Based in Dallas, Texas, AveXis is a synthetic biology platform company establishing unique industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus.